direct thrombin inhibitor


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia, Wikipedia.

direct thrombin inhibitor

Abbreviation: DP
Any medication or substance that interferes with the coagulation of blood by blocking the action of thrombin. Unlike heparins, which are anticoagulants that require the presence of antithrombin to inactivate thrombin, DTIs exert their effects without an intermediary. DTIs can be used to treat and prevent clots in both arteries and veins (although heparin and warfarin are usually preferred for these uses). They are an alternative to heparin in patients with a history of heparin-induced thrombocytopenia. The primary side effect of DTIs is bleeding.
See also: inhibitor
References in periodicals archive ?
Ecarin chromogenic assay--A new method for quantitative determination of direct thrombin inhibitors like hirudin.
Direct thrombin inhibitors are key in the treatment of HIT because thrombin plays a central role in HIT.
Direct Thrombin Inhibitors (DTIs): Argatroban, Lepirudin, Bivalirudin
The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
For chronic atrial fibrillation, the patient had received dabigatran (75 mg twice per day) for 12 months; dabigatran is a direct thrombin inhibitor that has recently been cleared by the US Food and Drug Administration for the prevention of stroke in patients with atrial fibrillation.
Angiomax, a direct thrombin inhibitor with a naturally reversible mechanism of action and a 25 minute half-life, is not approved for transcatheter aortic valve interventions.
Comparing the AVERROES results to those for the investigational direct thrombin inhibitor dabigatran in the 18,000-patient RELY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study (N.
Comparing the AVERROES results to those for the investigational direct thrombin inhibitor dabigatran in the 18,000-patient RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study (N.
M2 PHARMA-October 20, 2010-FDA approves oral direct thrombin inhibitor Pradaxa in patients with AFib(C)2010 M2 COMMUNICATIONS
The direct thrombin inhibitor is among several emerging oral anticoagulants that might replace warfarin, which has accumulated a notorious safety record over its 60-year history and requires frequent dose adjustments.
The 18,000-patient Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) study compared the safety and efficacy of two different dosages of the direct thrombin inhibitor dabigatran against warfarin in atrial fibrilation (AF) patients who also had at least one additional risk factor for stroke, including prior stroke, low left ventricular ejection fraction, or age 75 or older.